Immuron (ASX:IMC) has closed the financial year 2025 with record sales and significant progress across its clinical programs, positioning the company for another pivotal year ahead.
Global revenue rose 49 per cent to $7.3 million, driven by strong growth in its flagship traveller’s diarrhoea product Travelan. North America was the standout, with sales climbing 76 per cent to $2 million, driven by Amazon traction and expanded Canadian retail distribution. In Australia, sales increased by 40 per cent to $5.3 million, supported by the introduction of new pharmacy ranges. Gross margins remained robust at 65.4 per cent.
Profitability from hyperimmune products was steady at $1.35 million, despite a deliberate $1.4 million increase in selling and marketing investment to build momentum.
CEO Steven Lydeamore said Travelan had delivered consistent quarter-on-quarter growth and was proving its international potential. He added that the upcoming launch of ProIBS in early 2026 would create a new market opportunity for irritable bowel syndrome.
Clinical development advanced significantly during the year. Travelan (IMM-124E) completed full recruitment of 866 participants in an extensive US military-led field study, with topline results expected in October 2025. A parallel Phase 2 Controlled Human Infection Model trial involving 60 participants is also progressing, with an FDA End-of-Phase 2 meeting planned for the first half of 2026.
The company’s second key program, IMM-529 for Clostridioides difficile infection, is moving toward an Investigational New Drug submission to the US FDA by the end of September, with approval anticipated by December 2025. Meanwhile, IMM-986, targeting vancomycin-resistant enterococci, advanced through early-stage preclinical work in partnership with Monash University.
Immuron ended FY25 with $5.9 million in cash and term deposits, not including the additional $2.8 million raised in July 2025 through a Nasdaq placement. Management stated that the balance sheet provides a strong foundation for advancing its commercial and clinical pipeline.